ONKO ILAC SAN VE TIC A.S.

ONKO ILAC SAN VE TIC A.S. is a leading Turkish pharmaceutical company. It specializes in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. The company has a strong focus on specific therapeutic areas, particularly oncology, where it produces medicines for cancer treatment. Onko Ilac operates with a commitment to quality, innovation, and contributing to public health. It is actively involved in both the domestic Turkish market and international pharmaceutical operations, exporting its products and collaborating with global partners.

Factory or Trader:

ONKO ILAC SAN VE TIC A.S. is primarily a manufacturer (factory). While it also engages in trade and distribution of its manufactured products, its core business involves the production of pharmaceuticals.

ONKO ILAC SAN VE TIC A.S. primarily focuses on the production and sale of oncology drugs. Their product portfolio includes a range of antineoplastic agents and supportive care medications used in cancer treatment.

Key product categories and specific examples often include:

Chemotherapy Drugs:

Cytotoxic agents for various cancer types.

Examples may include formulations of paclitaxel, docetaxel, oxaliplatin, carboplatin, gemcitabine, and irinotecan.

Targeted Therapies:

Biological drugs that target specific molecules involved in cancer growth.

Examples could involve monoclonal antibodies or small molecule inhibitors relevant to oncology.

Supportive Care Products:

Medications designed to manage side effects of cancer treatment or improve quality of life for cancer patients.

This may include antiemetics, colony-stimulating factors, and pain management medications.

Biosimilars:

Biologic medical products that are highly similar to an already approved biological medicine.

ONKO ILAC may produce biosimilar versions of established oncology biologics.

Onko Ilac's specialization is in the oncology therapeutic area, providing both generic and biosimilar versions of critical cancer medications, as well as developing new formulations.